T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia
15 Februar 2024 - 10:02PM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection
of sepsis-causing pathogens and antibiotic resistant genes, today
announced the execution of territory exclusive distribution
agreements for new geographies in the Netherlands, Belgium, and
Vietnam, as well as the re-entry into Switzerland. Under the terms
of the agreements, T2 Biosystems will sell the T2Dx® Instrument,
the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance®
Panel into these countries through our distribution partners.
The execution of these territory exclusive
distribution agreements further expands T2 Biosystems’ commercial
business internationally. In the Netherlands, 140,000 patients were
admitted to the hospital with an infection. Belgium has launched a
national sepsis action plan set to launch in April 2024 and it is
estimated that over 40,000 Belgians develop sepsis each year.
Vietnam is emerging economy that has also been identified as a
hotspot for infectious diseases. In a study of five Asia-Pacific
countries, Vietnam had the highest prevalence of resistance.
Finally, T2 Biosystems’ current distribution
partner Biomedica, which secured the company’s second largest T2Dx
Instrument contract in company history during 2023 in Poland, is
re-entering the Switzerland market with T2 Biosystems’ sepsis
products. In 2017, Switzerland data indicated that 19,000 patients
suffered from sepsis and in 2023 a working group of leading
clinicians called for a Swiss Sepsis National Action Plan. The
introduction of the T2Dx Instrument and sepsis test panels into
these countries will allow rapid detection of sepsis-causing
pathogens and antibiotic resistance genes, in hours instead of
days, enabling clinicians to achieve faster targeted therapy.
"We are committed to expanding our
commercialization worldwide and these new distribution agreements
provide access to important markets in Europe and Asia,” said John
Sperzel, Chairman and CEO of T2 Biosystems. “We believe these
countries represent additional growth potential for our
culture-independent rapid diagnostics and look forward to building
lasting relationships with our newly appointed distributors as we
work to improve the quality of care for patients at risk of
sepsis.”
About T2 BiosystemsT2
Biosystems, a leader in the rapid detection of sepsis-causing
pathogens and antibiotic resistance genes, is dedicated to
improving patient care and reducing the cost of care by helping
clinicians effectively treat patients faster than ever before. T2
Biosystems’ products include the T2Dx® Instrument, the T2Bacteria®
Panel, the T2Candida® Panel, the T2Resistance® Panel, and the
T2Biothreat™ Panel, and are powered by the proprietary T2 Magnetic
Resonance (T2MR®) technology. T2 Biosystems has an active pipeline
of future products, including the U.S. T2Resistance Panel, the
Candida auris test, and the T2Lyme™ Panel. For more information,
please visit www.t2biosystems.com.
Investor Contact:Philip Trip
Taylor, Gilmartin Groupphilip@gilmartinIR.com 415-937-5406
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
Von Jun 2023 bis Jun 2024